New Approaches and Therapeutics Targeting Apoptosis in Disease
- 1 June 2005
- journal article
- review article
- Published by Elsevier in Pharmacological Reviews
- Vol. 57 (2) , 187-215
- https://doi.org/10.1124/pr.57.2.6
Abstract
Apoptosis, the major form of cellular suicide, is central to various physiological processes and the maintenance of homeostasis in multicellular organisms. Presumably, even more important is a causative or contributing role of apoptosis to various human diseases. These include situations with unwanted cell accumulation (cancer) and failure to eradicate aberrant cells (autoimmune diseases) or disorders with an inappropriate loss of cells (heart failure, stroke, AIDS, neurodegenerative diseases, and liver injury). The past decade has witnessed a tremendous progress in the knowledge of the molecular mechanisms that regulate apoptosis and the mediators that either prevent or trigger cell death. Consequently, apoptosis regulators have emerged as key targets for the design of therapeutic strategies aimed at modulating cellular life-and-death decisions. Numerous novel approaches are currently being followed employing gene therapy and antisense strategies, recombinant biologics, or classical organic and combinatorial chemistry to target specific apoptotic regulators. Convincing proof-of-principle evidence obtained in several animal models confirms the validity of strategies targeting apoptosis and revealed an enormous potential for therapeutic intervention in a variety of illnesses. Although numerous apoptotic drugs are currently being developed, several therapeutics have progressed to clinical testing or are already approved and marketed. Here we review the recent progress of apoptosis-based therapies and survey some highlights in a very promising field of drug development.Keywords
This publication has 194 references indexed in Scilit:
- Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumorsNature Medicine, 2004
- Inhibition of papain-like cysteine proteases and legumain by caspase-specific inhibitors: when reaction mechanism is more important than specificityCell Death & Differentiation, 2003
- IAP proteins: blocking the road to death's doorNature Reviews Molecular Cell Biology, 2002
- Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compoundNature Medicine, 2002
- The BH3 domain of BAD fused to the Antennapedia peptide induces apoptosis via its alpha helical structure and independent of Bcl-2Cell Death & Differentiation, 2001
- Protection against TNF-Induced Liver Parenchymal Cell Apoptosis during Endotoxemia by a Novel Caspase Inhibitor in MiceToxicology and Applied Pharmacology, 2000
- Intrathecal Administration of Neutralizing Antibody against Fas Ligand Suppresses the Progression of Experimental Autoimmune EncephalomyelitisBiochemical and Biophysical Research Communications, 2000
- A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines 1 1Edited by A. R. FershtJournal of Molecular Biology, 2000
- Locoregional Apo2L/TRAIL Eradicates Intracranial Human Malignant Glioma Xenografts in Athymic Mice in the Absence of NeurotoxicityBiochemical and Biophysical Research Communications, 1999
- A novel heterodimeric cysteine protease is required for interleukin-1βprocessing in monocytesNature, 1992